JP2021500880A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500880A5
JP2021500880A5 JP2020521360A JP2020521360A JP2021500880A5 JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5 JP 2020521360 A JP2020521360 A JP 2020521360A JP 2020521360 A JP2020521360 A JP 2020521360A JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5
Authority
JP
Japan
Prior art keywords
vector
adenovirus vector
expression cassette
monkey adenovirus
saladenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020521360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/078210 external-priority patent/WO2019076880A1/en
Publication of JP2021500880A publication Critical patent/JP2021500880A/ja
Publication of JP2021500880A5 publication Critical patent/JP2021500880A5/ja
Ceased legal-status Critical Current

Links

JP2020521360A 2017-10-16 2018-10-16 2つの発現カセットを有するサルアデノウイルスベクター Ceased JP2021500880A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572944P 2017-10-16 2017-10-16
US62/572,944 2017-10-16
PCT/EP2018/078210 WO2019076880A1 (en) 2017-10-16 2018-10-16 SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES

Publications (2)

Publication Number Publication Date
JP2021500880A JP2021500880A (ja) 2021-01-14
JP2021500880A5 true JP2021500880A5 (https=) 2021-11-25

Family

ID=63896161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521360A Ceased JP2021500880A (ja) 2017-10-16 2018-10-16 2つの発現カセットを有するサルアデノウイルスベクター

Country Status (10)

Country Link
US (2) US20200299651A1 (https=)
EP (1) EP3697918B1 (https=)
JP (1) JP2021500880A (https=)
CN (1) CN111479926A (https=)
AR (1) AR114989A1 (https=)
BR (1) BR112020007413A2 (https=)
CA (1) CA3084346A1 (https=)
ES (1) ES3056141T3 (https=)
MX (1) MX2020003746A (https=)
WO (1) WO2019076880A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN119770638A (zh) 2019-09-30 2025-04-08 吉利德科学公司 Hbv疫苗和治疗hbv的方法
AU2021213121A1 (en) * 2020-01-28 2022-08-18 Codagenix Inc. Deoptimized SARS-CoV-2 and methods and uses thereof
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
WO2005106002A2 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
JP2012504387A (ja) 2008-09-27 2012-02-16 ウィトリシティ コーポレーション 無線エネルギー伝達システム
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
WO2013052859A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN106659777A (zh) * 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品
CN107921118B (zh) 2015-06-12 2022-11-08 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection

Similar Documents

Publication Publication Date Title
Chang Adenovirus vectors: excellent tools for vaccine development
Zhao et al. Viral vector‐based gene therapies in the clinic
JP2017514483A5 (https=)
JP2021500880A5 (https=)
Tatsis et al. Adenoviruses as vaccine vectors
CN103998604B (zh) Hbv聚合酶突变体
RU2016146664A (ru) Аденовирус, содержащий альбумин-связывающий участок
JP2014516536A5 (https=)
JP2016538885A5 (https=)
JP2019523648A5 (https=)
JP2015506179A5 (https=)
JP2014503206A5 (https=)
JP2018537984A5 (https=)
JP2018520997A5 (https=)
JP2019526580A5 (https=)
JP2016539946A5 (https=)
CA2863964A1 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
JP2019520841A5 (https=)
Nguyen et al. Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
CN113226364A (zh) 组合物和方法
JP2020537526A5 (https=)
Bisgin et al. Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination
JP2020527167A5 (https=)
JP2018526994A5 (https=)